{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.83","statisticalMethod":"Kruskal-Wallis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.0","upperLimit":"1.0","value":"0.0"},{"groupId":"OG001","lowerLimit":"-4.5","upperLimit":"1.0","value":"-0.5"},{"groupId":"OG002","lowerLimit":"-3.0","upperLimit":"0.0","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"Major Depression Inventory (MDI)-score, Baseline, 6 months, one year (week 52)., change between baseline and 1 year reported.\n\nThe Major Depression Inventory (MDI) is a mood questionnaire developed by the World Health Organization. To calculate the total score, a sum of ten individual items (each with an individual score between 0-5, with 0 indicating absence of a symptom and 5 indicating constant presence of a given symptom) is used. A higher score signifies deeper depression with 50 being the maximum score.","dispersionType":"Inter-Quartile Range","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final collection of MDI-questionnaires.","reportingStatus":"POSTED","timeFrame":"Baseline, 6 mths, one year.","title":"Change MDI-score","type":"SECONDARY","unitOfMeasure":"MDI-score"}